

# Giles W Robinson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1168979/publications.pdf>

Version: 2024-02-01

108  
papers

11,011  
citations

101384

36  
h-index

35952

97  
g-index

116  
all docs

116  
docs citations

116  
times ranked

13392  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	13.7	1,872
2	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	13.7	787
3	Novel mutations target distinct subgroups of medulloblastoma. <i>Nature</i> , 2012, 488, 43-48.	13.7	742
4	Subtypes of medulloblastoma have distinct developmental origins. <i>Nature</i> , 2010, 468, 1095-1099.	13.7	710
5	Medulloblastomics: the end of the beginning. <i>Nature Reviews Cancer</i> , 2012, 12, 818-834.	12.8	560
6	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	12.5	540
7	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	13.7	520
8	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	3.9	478
9	Medulloblastoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 11.	18.1	376
10	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. <i>Journal of Clinical Oncology</i> , 2015, 33, 2646-2654.	0.8	368
11	Resolving medulloblastoma cellular architecture by single-cell genomics. <i>Nature</i> , 2019, 572, 74-79.	13.7	273
12	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	5.1	268
13	A Mouse Model of the Most Aggressive Subgroup of Human Medulloblastoma. <i>Cancer Cell</i> , 2012, 21, 168-180.	7.7	250
14	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , 2019, 138, 309-326.	3.9	180
15	Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. <i>BMC Cancer</i> , 2014, 14, 258.	1.1	162
16	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 768-784.	5.1	151
17	Medulloblastomics revisited: biological and clinical insights from thousands of patients. <i>Nature Reviews Cancer</i> , 2020, 20, 42-56.	12.8	147
18	Medulloblastoma—translating discoveries from the bench to the bedside. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 714-722.	12.5	145

#	ARTICLE	IF	CITATIONS
19	Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. <i>Nature Communications</i> , 2018, 9, 3962.	5.8	142
20	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 2433-2441.	3.2	134
21	Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma. <i>Cancer Cell</i> , 2014, 25, 516-529.	7.7	128
22	Role of MYC in Medulloblastoma. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2013, 3, a014308-a014308.	2.9	123
23	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. <i>Nature Genetics</i> , 2015, 47, 263-266.	9.4	109
24	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	0.8	106
25	Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. <i>Oncotarget</i> , 2017, 8, 69295-69302.	0.8	99
26	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	13.7	94
27	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. <i>Cancer Discovery</i> , 2021, 11, 3008-3027.	7.7	88
28	The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced Ototoxicity in Children With Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 252-259.	2.3	80
29	Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. <i>Cancer</i> , 2018, 124, 4168-4180.	2.0	64
30	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	7.7	64
31	Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. <i>Neuro-Oncology</i> , 2019, 21, 1319-1330.	0.6	63
32	Zeb1 controls neuron differentiation and germinal zone exit by a mesenchymal-epithelial-like transition. <i>ELife</i> , 2016, 5, .	2.8	60
33	Germline <i>GPR161</i> Mutations Predispose to Pediatric Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-50.	0.8	50
34	Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10009-10009.	0.8	49
35	mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma. <i>Developmental Cell</i> , 2017, 43, 673-688.e5.	3.1	48
36	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. <i>Acta Neuropathologica</i> , 2020, 140, 209-225.	3.9	45

#	ARTICLE	IF	CITATIONS
37	Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). <i>Oncotarget</i> , 2020, 11, 1942-1952.	0.8	45
38	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	3.9	44
39	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). <i>Journal of Clinical Oncology</i> , 2020, 38, 223-231.	0.8	40
40	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	0.8	40
41	Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i> , <i>ROS1</i> , or <i>ALK</i> aberrations (STARTRK-NC). <i>Neuro-Oncology</i> , 2022, 24, 1776-1789.	0.6	37
42	Concordance between the chang and the International Society of Pediatric Oncology (<sc>SIOP</sc>) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 601-605.	0.8	36
43	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. <i>Acta Neuropathologica</i> , 2020, 139, 259-271.	3.9	36
44	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. <i>Clinical Cancer Research</i> , 2021, 27, 2879-2889.	3.2	35
45	Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. <i>Neuro-Oncology</i> , 2021, 23, 1586-1596.	0.6	35
46	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. <i>Nature Communications</i> , 2021, 12, 4089.	5.8	27
47	Lorlatinib in a Child with <i>ALK</i> -Fusion-Positive High-Grade Glioma. <i>New England Journal of Medicine</i> , 2021, 385, 761-763.	13.9	27
48	Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	26
49	Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 27-35.	1.1	25
50	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28879.	0.8	24
51	Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10525-10525.	0.8	24
52	Computerized assessment of cognitive impairment among children undergoing radiation therapy for medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 403-411.	1.4	21
53	Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 362-371.	1.1	17
54	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1116-1122.	1.7	15

#	ARTICLE	IF	CITATIONS
55	Characterizing Posterior Fossa Syndrome: A Survey of Experts. <i>Pediatric Neurology</i> , 2020, 104, 19-22.	1.0	15
56	Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 107-107.	0.8	15
57	Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 47-53.	0.4	14
58	Exposureâ€™Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. <i>Clinical Cancer Research</i> , 2020, 26, 1563-1573.	3.2	14
59	Genomics Paves the Way for Better Infant Medulloblastoma Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2010-2013.	0.8	14
60	Primary cilia control translation and the cell cycle in medulloblastoma. <i>Genes and Development</i> , 2022, 36, 737-751.	2.7	14
61	Atypical teratoid/rhabdoid tumor (ATRT) arising from the 3rd cranial nerve in infants: a clinical-radiological entity?. <i>Journal of Neuro-Oncology</i> , 2015, 124, 175-183.	1.4	12
62	Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases. <i>Child's Nervous System</i> , 2018, 34, 605-610.	0.6	12
63	Preclinical studies of 5-fluoro-2â€™-deoxycytidine and tetrahydrouridine in pediatric brain tumors. <i>Journal of Neuro-Oncology</i> , 2016, 126, 225-234.	1.4	11
64	Evaluating pediatric spinal low-grade gliomas: a 30-year retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2019, 145, 519-529.	1.4	11
65	Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility. <i>Laboratory Investigation</i> , 2022, 102, 134-142.	1.7	11
66	Medulloblastoma: advances and challenges. <i>F1000 Biology Reports</i> , 2011, 3, 5.	4.0	9
67	Impact of tumor location on medulloblastoma subtyping and treatment (Commentary on teo et al.,) Tj ETQq1 1 0.784314 rgBT /Over 0,8	0.8	9
68	Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28756.	0.8	9
69	Ovulation induction and oocyte retrieval for fertility preservation in young adolescents newly diagnosed with medulloblastoma: a case series. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 878-879.	0.4	7
70	FDGâ€™PET CT in the evaluation of primary and secondary pancreatic malignancies. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27115.	0.8	7
71	Reoperation for Medulloblastoma Prior to Adjuvant Therapy. <i>Neurosurgery</i> , 2019, 84, 1050-1058.	0.6	7
72	WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. <i>Acta Neuropathologica</i> , 2020, 140, 595-597.	3.9	7

#	ARTICLE	IF	CITATIONS
73	ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age. A report from the Children Oncology Group.. Journal of Clinical Oncology, 2017, 35, 10505-10505.	0.8	7
74	Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. Neuro-Oncology, 0, , .	0.6	7
75	Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. Pediatric Blood and Cancer, 2015, 62, 1855-1858.	0.8	6
76	Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial. Neuro-Oncology Advances, 2021, 3, vdaa168.	0.4	6
77	Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies. Clinical Pharmacology and Therapeutics, 2017, 102, 752-753.	2.3	5
78	[11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. Journal of Nuclear Medicine, 2021, , jnumed.120.261891.	2.8	4
79	Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors.. Journal of Clinical Oncology, 2020, 38, 10542-10542.	0.8	4
80	Developmental origins of neural tumours: old idea, new approaches. Neuropathology and Applied Neurobiology, 2012, 38, 222-227.	1.8	3
81	The RACE to Develop New Targeted Therapies for Children With CNS Tumors. Clinical Pharmacology and Therapeutics, 2020, 108, 434-436.	2.3	3
82	Food Is Love: Partnering With Families to Provide Nourishment at the End of Life. Journal of Clinical Oncology, 2020, 38, 1864-1867.	0.8	3
83	Exploiting Laboratory Insights to Improve Outcomes of Pediatric Central Nervous System Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e540-e546.	1.8	2
84	Non-Malignant Cerebrospinal Fluid Ascites in a Patient with Atypical Teratoid Rhabdoid Tumor. Oncology Research and Treatment, 2017, 40, 216-219.	0.8	2
85	Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro-Oncology, 2022, 24, 1166-1175.	0.6	2
86	Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients. STAR Protocols, 2022, 3, 101292.	0.5	2
87	LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG). Neuro-Oncology, 2022, 24, i92-i92.	0.6	2
88	Dunn Index Bootstrap (DIBS): A procedure to empirically select a cluster analysis method that identifies biologically and clinically relevant molecular disease subgroups. BMC Bioinformatics, 2015, 16, P12.	1.2	1
89	Rare cases of medulloblastoma with hypermutation. Cancer Reports, 2021, , e1521.	0.6	1
90	Abstract 3448: Subtypes of medulloblastoma have distinct developmental origins. , 2011, , .		1

#	ARTICLE	IF	CITATIONS
91	Outcomes for young children with molecularly defined ependymoma treated on the multi-institutional SJYC07 clinical trial.. Journal of Clinical Oncology, 2018, 36, 10548-10548.	0.8	1
92	Exploiting Laboratory Insights to Improve Outcomes of Pediatric Central Nervous System Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e540-e546.	1.8	1
93	Pretreatment Normal WM Magnetization Transfer Ratio Predicts Risk of Radiation Necrosis in Patients with Medulloblastoma. American Journal of Neuroradiology, 2022, 43, 299-303.	1.2	1
94	MEDB-69. Clinical and molecular meta-analysis of three major medulloblastoma clinical trials (ACNS0331, SJMB03, ACNS0332) uncovers novel strategies to improve risk-stratified therapy. Neuro-Oncology, 2022, 24, i122-i122.	0.6	1
95	MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 2022, 24, i124-i125.	0.6	1
96	ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis. Neuro-Oncology, 2022, 24, i8-i8.	0.6	1
97	Reply to "Assembling the brain trust: the multidisciplinary imperative in neuro-oncology". Nature Reviews Clinical Oncology, 2019, 16, 522-523.	12.5	0
98	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer. , 2021, , .		0
99	Abstract 1434: A mouse model of the most aggressive subgroup of human medulloblastoma. , 2012, , .		0
100	Use of whole genome sequencing to identify novel mutations in distinct subgroups of medulloblastoma.. Journal of Clinical Oncology, 2012, 30, 9518-9518.	0.8	0
101	Developmental pharmacokinetics of topotecan (TPT), a renally excreted drug, in infants and young children with brain tumors.. Journal of Clinical Oncology, 2015, 33, 10055-10055.	0.8	0
102	Factors influencing the intracellular exposure of gemcitabine triphosphate in children with CNS tumors.. Journal of Clinical Oncology, 2019, 37, e13547-e13547.	0.8	0
103	BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. Neuro-Oncology, 2021, 23, vi18-vi19.	0.6	0
104	The posterior fossa syndrome questionnaire: using science to inform practice. Journal of Neuro-Oncology, 2022, , 1.	1.4	0
105	MEDB-42. Germline <i>Elp1</i> deficiency promotes genomic instability and survival of granule neuron progenitors primed for SHH medulloblastoma pathogenesis. Neuro-Oncology, 2022, 24, i115-i115.	0.6	0
106	EPCT-01. Pediatric Brain Tumor Consortium (PBTC)-055: A phase I study of trametinib and hydroxychloroquine (HCQ) for BRAF-fusion or Neurofibromatosis type-1 (NF1)-associated pediatric gliomas. Neuro-Oncology, 2022, 24, i35-i35.	0.6	0
107	MEDB-29. Application of Rotterdam Post-Operative Cerebellar Mutism Syndrome Prediction Model to Patients Operated for Medulloblastoma in a Single Institution. Neuro-Oncology, 2022, 24, i111-i111.	0.6	0
108	INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.. Neuro-Oncology, 2022, 24, i188-i188.	0.6	0